[BREAKING] Hemerion obtains the FDA clearance for its next US clinical trial


Surgeon using Hemerion technology

Improving local control of glioblastoma: Hemerion technology presented at the 2023 Congress of the French Society of Neurosurgery

Maximilien Vermandel and Prof. Nicolas Reyns are organizing a demonstration of the Hemerion technology associated with the surgical treatment of glioblastoma during the 2023 Congress of the French Society of Neurosurgery.

Organized on March 15 at 4:00 pm in Lille Grand Palais, the demonstration will detail the mechanism of action and the functioning of the new treatment platform combining a photosensitizing drug, Pentalafen®, and an illumination system, Heliance® Solution.

Prof. Reyns, Hemerion’s scientific advisor, will detail the practical and clinical application of the Hemerion technology in the operating room, in the context of glioblastoma surgery.

He will also comment on the first results of the Phase I clinical study sponsored by the Lille University Hospital and the future Phase II trials set up by Hemerion.

Our team will be present throughout the congress: do not hesitate to come and meet us to discuss the perspectives opened by our technologies.

Learn more about Hemerion technology.